Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
9.26
-0.24 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
9.15
-0.11 (-1.19%)
After-hours: Apr 28, 2026, 7:52 PM EDT
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $442.34 million as of April 28, 2026. Its market cap has increased by 465.13% in one year.
Market Cap
442.34M
Enterprise Value
282.23M
1-Year Change
465.13%
Ranking
Category
Stock Price
$9.26
Market Cap Chart
Since August 10, 2021, Climb Bio's market cap has increased from $403.20M to $442.34M, an increase of 9.71%. That is a compound annual growth rate of 1.98%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 27, 2026 | 453.80M | 137.62% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Contineum Therapeutics | 478.65M |
| Valneva SE | 470.89M |
| Candel Therapeutics | 470.25M |
| Entrada Therapeutics | 467.64M |
| Prelude Therapeutics | 462.54M |
| Larimar Therapeutics | 462.28M |
| Aura Biosciences | 461.60M |
| REGENXBIO | 453.72M |